Roche

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Roche and other ETFs, options, and stocks.

About RHHBY

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. 

CEO
Thomas Schinecker
CEOThomas Schinecker
Employees
103,249
Employees103,249
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1896
Founded1896
Employees
103,249
Employees103,249

RHHBY Key Statistics

Market cap
322.14B
Market cap322.14B
Price-Earnings ratio
26.02
Price-Earnings ratio26.02
Dividend yield
1.92%
Dividend yield1.92%
Average volume
2.76M
Average volume2.76M
High today
$49.20
High today$49.20
Low today
$46.15
Low today$46.15
Open price
$48.32
Open price$48.32
Volume
2.80M
Volume2.80M
52 Week high
$49.20
52 Week high$49.20
52 Week low
$34.10
52 Week low$34.10

Stock Snapshot

The current Roche(RHHBY) stock price is $48.87, with a market capitalization of 322.14B. The stock trades at a price-to-earnings (P/E) ratio of 26.02 and offers a dividend yield of 1.9%.

As of 2025-11-19, Roche(RHHBY) stock has fluctuated between $46.15 and $49.20. The current price stands at $48.87, placing the stock +5.9% above today's low and -0.7% off the high.

The Roche(RHHBY)'s current trading volume is 2.8M, compared to an average daily volume of 2.76M.

In the last year, Roche(RHHBY) shares hit a 52-week high of $49.20 and a 52-week low of $34.10.

In the last year, Roche(RHHBY) shares hit a 52-week high of $49.20 and a 52-week low of $34.10.

RHHBY News

Investor's Business Daily 16h
Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200%

Biotech stock Olema Pharmaceuticals (OLMA) catapulted to a four-year high Tuesday, up more than 200%, after Roche (RHHBY) unveiled positive results for its riva...

Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200%
TipRanks 16h
Olema Oncology price target raised to $45 from $22 at Oppenheimer

Oppenheimer raised the firm’s price target on Olema Oncology to $45 from $22 and keeps an Outperform rating on the shares. The firm notes Olema (OLMA) shares ar...

Investor's Business Daily 2d
Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer

Shares of Jazz Pharmaceuticals (JAZZ) and Zymeworks (ZYME) catapulted Monday after the duo unveiled positive test results for a drug that could eventually rattl...

Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer

Analyst ratings

48%

of 23 ratings
Buy
47.8%
Hold
30.4%
Sell
21.7%

More RHHBY News

Nasdaq 7d
RHHBY Reaches Analyst Target Price

In recent trading, shares of RHHBY (Symbol: RHHBY) have crossed above the average analyst 12-month target price of $44.88, changing hands for $45.43/share. When...

RHHBY Reaches Analyst Target Price
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.